Malvern Instrument?s to Acquire MicroCal Business from GE Healthcare Life Sciences
Malvern Instruments Ltd has entered into an agreement with GE Healthcare Life Sciences to acquire the company’s MicroCal microcalorimetry business. Financial terms were not disclosed. The acquisition, which is subject to regulatory approvals, is expected to complete in the third quarter of 2014.
MicroCal has a 30-year history of developing and supplying easy-to-use microcalorimeters. These systems are used extensively to study proteins and other biomolecules in drug discovery and development. The acquisition of MicroCal will further strengthen Malvern’s rapidly expanding portfolio of analytical solutions for customers in core pharmaceutical and biopharmaceutical markets. Within Malvern, MicroCal will retain its key location in Northampton, Massachusetts and will become an integral part of the Malvern business.
Paul Walker, Managing Director of Malvern Instruments, said: “Microcalorimetry is now an essential tool that is used at almost every stage of the drug discovery, development and formulation process. MicroCal is an established technology leader in the field. MicroCal products are an excellent fit with Malvern’s existing portfolio of measurement solutions for the pharmaceutical and biopharmaceutical industries. Their ability to deliver information about drug binding and protein stability is entirely complementary to Malvern’s current products and to those in development. This addition to our business will have an immediate impact on Malvern’s ability to provide a complete range of instrumentation solutions and support across life science research and development. I very much look forward to welcoming the talented MicroCal team into the Malvern family.”
Headquartered in the UK, Malvern Instruments is a global business that serves a diverse range of academic and industrial markets, providing instrumentation for the analysis of a wide variety of materials. The company is part of the Materials Analysis Division of Spectris plc.
MicroCal differential scanning calorimeters (DSC) and isothermal titration calorimeters (ITC) are used in areas from basic research to the discovery and development of small molecules, biotherapeutics and vaccines. Customers are based in pharmaceutical, biotech, academic and government organizations around the worldwide.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance